Tarlatamab: The Immunotherapy Beating Chemotherapy in Small Cell Lung Ca...
Tarlatamab: The Immunotherapy Beating Chemotherapy in Small Cell Lung Cancer
For decades, small cell lung cancer has been one of the hardest cancers to treat. But a new drug, Tarlatamab, is changing everything. Unlike chemotherapy, which attacks both healthy and cancerous cells, Tarlatamab uses the body’s own immune system to target tumors with precision.
In this video, we’ll uncover:
✅ How Tarlatamab works as a bispecific T-cell engager
✅ Why it’s outperforming chemotherapy in trials
✅ What this breakthrough means for lung cancer patients
✅ The future of immunotherapy in oncology
π If you believe in the power of science to change lives, hit subscribe and join us as we explore the most exciting medical breakthroughs of 2025.
Comments
Post a Comment